Evidence map›Paper›PMID 39354041›Full record

ArticleScientific reports2024

Improved longevity of actomyosin in vitro motility assays for sustainable lab-on-a-chip applications.

Andreas Melbacke, Aseem Salhotra, Marko Ušaj, Alf Månsson

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andreas MelbackeDepartment of Chemistry and Biomedical Sciences, Linnaeus University, 39182, Kalmar, Sweden.
Aseem SalhotraDepartment of Chemistry and Biomedical Sciences, Linnaeus University, 39182, Kalmar, Sweden.ORCID 0000-0003-4835-0598
Marko UšajDepartment of Chemistry and Biomedical Sciences, Linnaeus University, 39182, Kalmar, Sweden. marko.usaj@lnu.se.ORCID 0000-0001-6662-8886
Alf MånssonDepartment of Chemistry and Biomedical Sciences, Linnaeus University, 39182, Kalmar, Sweden. alf.mansson@lnu.se.ORCID 0000-0002-5889-7792

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the in vitro motility assay (IVMA), actin filaments are observed while propelled by surface-adsorbed myosin motor fragments such as heavy meromyosin (HMM). In addition to fundamental studies, the IVMA is the basis for a range of lab-on-a-chip applications, e.g. transport of cargoes in nanofabricated channels in nanoseparation/biosensing or the solution of combinatorial mathematical problems in network-based biocomputation. In these applications, prolonged myosin function is critical as is the potential to repeatedly exchange experimental solutions without functional deterioration. We here elucidate key factors of importance in these regards. Our findings support a hypothesis that early deterioration in the IVMA is primarily due to oxygen entrance into in vitro motility assay flow cells. In the presence of a typically used oxygen scavenger mixture (glucose oxidase, glucose, and catalase), this leads to pH reduction by a glucose oxidase-catalyzed reaction between glucose and oxygen but also contributes to functional deterioration by other mechanisms. Our studies further demonstrate challenges associated with evaporation and loss of actin filaments with time. However, over 8 h at 21-26 °C, there is no significant surface desorption or denaturation of HMM if solutions are exchanged manually every 30 min. We arrive at an optimized protocol with repeated exchange of carefully degassed assay solution of 45 mM ionic strength, at 30 min intervals. This is sufficient to maintain the high-quality function in an IVMA over 8 h at 21-26 °C, provided that fresh actin filaments are re-supplied in connection with each assay solution exchange. Finally, we demonstrate adaptation to a microfluidic platform and identify challenges that remain to be solved for real lab-on-a-chip applications.

Indexed as

ActomyosinLab-On-A-Chip DevicesActin CytoskeletonAnimalsCatalaseGlucoseGlucose OxidaseHydrogen-Ion ConcentrationOxygenActomyosinCatalaseGlucoseGlucose OxidaseOxygenActomyosinBiosensingIn vitro motility assayLab-on-a-chipMicrofluidicsNetwork based biocomputation

Identifiers

PMID39354041
PMCPMC11445438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.